BridgeBio Oncology Therapeutics (BBOT) Amortizatization of Intangibles (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Amortizatization of Intangibles of $74000.0 for Q1 2026, down 32.73% sequentially from $110000.0 in Q4 2025, and down 81.86% YoY from $408000.0 in Q1 2025.
Powered by 
Analysis
BridgeBio Oncology Therapeutics (BBOT) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Amortizatization of Intangibles for 2 years, with the latest figure at $74000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 81.86% year-over-year to $74000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $592000.0 (changed N/A YoY) and the FY2025 annual result came in at $330000.0, changed N/A from the prior year.
- Amortizatization of Intangibles slipped to $74000.0 in Q1 2026 per BBOT's latest filing, from $110000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $408000.0 in Q1 2025 and troughed at $74000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | BridgeBio Oncology Therapeutics | 723.69 Mn | 497.98 Mn | - | -405,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -405,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | 1.04 Mn |
| Sep 30, 2025 | -577,000.00 |
| Jun 30, 2025 | 389,000.00 |
| Mar 31, 2025 | 408,000.00 |
| Dec 31, 2024 | 1.54 Mn |